Centre will help companies of all sizes to develop the next generation of biologic products
Work has officially started on the construction of the £38m National Biologics Manufacturing Centre (NBMC) in Central Park, Darlington.
Due for completion in 2015, the 5000m2 NBMC, which will be managed by the UK\'s Centre for Process Innovation (CPI), is part of the Government’s strategy to strengthen the UK’s life science sector.
The CPI says the NBMC will enable the biopharmaceutical industry to capitalise on its strong research and development pipeline and make more therapies available for unmet clinical needs. It will be a large open access facility that will help companies of all sizes to develop, prove, prototype and scale up the next generation of biologic products, processes and technology.
The CPI will promote collaboration with industry across the supply chain from research through to manufacture and clinic.
Dr Chris Dowle, CPI’s Director of Biologics, said: \'We are delighted to herald this groundbreaking to progress the journey to the new centre as we work with industry and academia to deliver new innovation to enhance the competitiveness of the UK biologics economy.\'